...
首页> 外文期刊>International Journal of Reproduction, Contraception, Obstetrics and Gynecology >Weight gain and menstrual abnormalities between users of Depo-provera and Noristerat
【24h】

Weight gain and menstrual abnormalities between users of Depo-provera and Noristerat

机译:Depo-provera和Noristerat使用者之间的体重增加和月经异常

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Progesterone only injectable contraceptive provides long acting contraception against unwanted pregnancy. Alterations in menstrual pattern are a well known side effect of this effective contraceptive method. Objective of this study was to compare the weight gain and pattern of menstrual abnormalities in users of Depot Medroxyprogesterone Acetate (DMPA) and Norethisterone Enanthate (Noristerat) in LASUTH. Methods: Retrospective comparative study conducted over a 3year period (January 2013 to December 2015) and involving 237 subjects who used injectable hormonal contraceptive (either DMPA or Noristerat). Case records of all the subjects were retrieved and information obtained on socio-demographic data, parity, previous contraceptive method and reason for discontinuation within one year of usage. Other information including subjects’ weight, menstrual cycle length and pattern, and side effects were collected at 3, 6 and 12 months for DMPA group and 2, 4 and 12 months interval for Noristerat group. Data obtained were analyzed using statistical packages for social sciences (version 19). Results: The combined mean age was 34.15±1.36 years. The mean weight at commencement was 68.16kg for DMPA and 66.61kg for Noristerat users while after a year, it significantly increased to 71.27kg for DMPA and 69.07kg for Noristerat users (P0.05). No change in menstrual pattern was noted in 10% of DMPA and 7% of Noristerat users while 60% of DMPA and 57% of Noristerat had amenorrhoea by the end one year period. Five percent each of DMPA and Noristerat users perceived weight gain as problem significant enough to discontinue both methods respectively. Overall, 24% of DMPA and 19.1% of Noristerat users discontinued use after one year. Conclusions: There were significant weight gain between users of DMPA and Noristerat which was not considered a problem. Amenorrhoea was the commonest menstrual abnormality responsible for discontinuation of either method.
机译:背景:仅孕激素注射避孕药可提供长效避孕药,以防止意外怀孕。月经方式的改变是这种有效避孕方法的众所周知的副作用。这项研究的目的是比较LASUTH醋酸甲羟孕酮(DMPA)和庚酸炔诺酮(Noristerat)使用者的体重增加和月经异常的方式。方法:回顾性比较研究历时3年(2013年1月至2015年12月),涉及237名使用可注射激素避孕药(DMPA或Noristerat)的受试者。检索所有受试者的病例记录,并获得有关社会人口统计学数据,奇偶性,以前的避孕方法以及使用一年内停用原因的信息。 DMPA组分别在3、6和12个月,Noristerat组分别在2、4和12个月的间隔中收集其他信息,包括受试者的体重,月经周期长度和方式以及副作用。使用社会科学统计软件包(版本19)对获得的数据进行了分析。结果:合并平均年龄为34.15±1.36岁。 DMPA开始使用时的平均体重为68.16kg,Noristerat用户使用时为66.61kg,而一年后,DMPA的平均体重显着增加至Noristerat用户使用时为69.07kg(P <0.05)。到一年末时,有10%的DMPA和7%的Noristerat使用者的经期没有变化,而60%的DMPA和57%的Noristerat则患有闭经。 DMPA和Noristerat用户中有5%的人认为体重增加是一个严重问题,足以分别终止两种方法。总体而言,一年后,有24%的DMPA和19.1%的Noristerat用户停止使用。结论:DMPA和Noristerat的使用者之间有明显的体重增加,这不算问题。闭经是导致这两种方法中止的最常见的月经异常。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号